Zobrazeno 1 - 10
of 624
pro vyhledávání: '"C. Haffner"'
Autor:
Alvaro Quintanal-Villalonga, Kenta Kawasaki, Esther Redin, Fathema Uddin, Swanand Rakhade, Vidushi Durani, Amin Sabet, Moniquetta Shafer, Wouter R. Karthaus, Samir Zaidi, Yingqian A. Zhan, Parvathy Manoj, Harsha Sridhar, Dennis Kinyua, Hong Zhong, Barbara P. Mello, Metamia Ciampricotti, Umesh K. Bhanot, Irina Linkov, Juan Qiu, Radhika A. Patel, Colm Morrissey, Sanjoy Mehta, Jesse Barnes, Michael C. Haffner, Nicholas D. Socci, Richard P. Koche, Elisa de Stanchina, Sonia Molina-Pinelo, Sohrab Salehi, Helena A. Yu, Joseph M. Chan, Charles M. Rudin
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract Neuroendocrine (NE) transformation is a mechanism of resistance to targeted therapy in lung and prostate adenocarcinomas leading to poor prognosis. Up to date, even if patients at high risk of transformation can be identified by the occurren
Externí odkaz:
https://doaj.org/article/501fe4c8a5e9423ca573e0d9f455d0b2
Autor:
Azra Ajkunic, Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman, Navonil De Sarkar, Brian Hanratty, Mohamed Adil, Jimmy Zhao, Samir Zaidi, Lawrence D. True, Jamie M. Sperger, Heather H. Cheng, Evan Y. Yu, Robert B. Montgomery, Jessica E. Hawley, Gavin Ha, Thomas Persse, Patricia Galipeau, John K. Lee, Stephanie A. Harmon, Eva Corey, Joshua M. Lang, Charles L. Sawyers, Colm Morrissey, Michael T. Schweizer, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Therapeutic approaches targeting proteins on the surface of cancer cells have emerged as an important strategy for precision oncology. To capitalize on the potential impact of drugs targeting surface proteins, detailed knowledge about the ex
Externí odkaz:
https://doaj.org/article/cdd085eaf0e84556a25f843f3b873e3c
Autor:
Sheng-You Liao, Dmytro Rudoy, Sander B. Frank, Luan T. Phan, Olga Klezovitch, Julian Kwan, Ilsa Coleman, Michael C. Haffner, Dapei Li, Peter S. Nelson, Andrew Emili, Valeri Vasioukhin
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract SND1 and MTDH are known to promote cancer and therapy resistance, but their mechanisms and interactions with other oncogenes remain unclear. Here, we show that oncoprotein ERG interacts with SND1/MTDH complex through SND1’s Tudor domain. E
Externí odkaz:
https://doaj.org/article/4403e3302e9b4f26a416658e94332b3c
Autor:
Yuri Tolkach, Vlado Ovtcharov, Alexey Pryalukhin, Marie-Lisa Eich, Nadine Therese Gaisa, Martin Braun, Abdukhamid Radzhabov, Alexander Quaas, Peter Hammerer, Ansgar Dellmann, Wolfgang Hulla, Michael C. Haffner, Henning Reis, Ibrahim Fahoum, Iryna Samarska, Artem Borbat, Hoa Pham, Axel Heidenreich, Sebastian Klein, George Netto, Peter Caie, Reinhard Buettner
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-9 (2023)
Abstract Pathologic examination of prostate biopsies is time consuming due to the large number of slides per case. In this retrospective study, we validate a deep learning-based classifier for prostate cancer (PCA) detection and Gleason grading (AI t
Externí odkaz:
https://doaj.org/article/21c0c2f5c021418b81a6adbfc9cf02b8
Autor:
Vipul Bhatia, Nikhil V. Kamat, Tiffany E. Pariva, Li-Ting Wu, Annabelle Tsao, Koichi Sasaki, Huiyun Sun, Gerardo Javier, Sam Nutt, Ilsa Coleman, Lauren Hitchcock, Ailin Zhang, Dmytro Rudoy, Roman Gulati, Radhika A. Patel, Martine P. Roudier, Lawrence D. True, Shivani Srivastava, Colm M. Morrissey, Michael C. Haffner, Peter S. Nelson, Saul J. Priceman, Jun Ishihara, John K. Lee
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-23 (2023)
Abstract Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in letha
Externí odkaz:
https://doaj.org/article/ba31d0647dda46c882a031a7d7f3aece
Autor:
Daniel J. Turnham, Manisha S. Mullen, Nicholas P. Bullock, Kathryn L. Gilroy, Anna E. Richards, Radhika Patel, Marcos Quintela, Valerie S. Meniel, Gillian Seaton, Howard Kynaston, Richard W. E. Clarkson, Toby J. Phesse, Peter S. Nelson, Michael C. Haffner, John N. Staffurth, Helen B. Pearson
Publikováno v:
Cells, Vol 13, Iss 8, p 673 (2024)
As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroendocrine (NE)
Externí odkaz:
https://doaj.org/article/1e39ec5e9d2d4ad899c5d22bfe802b4a
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer
Autor:
Preston D. Crowell, Jenna M. Giafaglione, Anthony E. Jones, Nicholas M. Nunley, Takao Hashimoto, Amelie M.L. Delcourt, Anton Petcherski, Raag Agrawal, Matthew J. Bernard, Johnny A. Diaz, Kylie Y. Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M. Navone, Huihui Ye, Amina Zoubeidi, Heather R. Christofk, Matthew B. Rettig, Robert E. Reiter, Michael C. Haffner, Paul C. Boutros, Orian S. Shirihai, Ajit S. Divakaruni, Andrew S. Goldstein
Publikováno v:
Cell Reports, Vol 42, Iss 10, Pp 113221- (2023)
Summary: Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistance. It is critical to understand how prostate tumor
Externí odkaz:
https://doaj.org/article/918185a092bc44e997b51df4ec5e68c1
Autor:
Thomas C. Westbrook, Xiangnan Guan, Eva Rodansky, Diana Flores, Chia Jen Liu, Aaron M. Udager, Radhika A. Patel, Michael C. Haffner, Ya-Mei Hu, Duanchen Sun, Tomasz M. Beer, Adam Foye, Rahul Aggarwal, David A. Quigley, Jack F. Youngren, Charles J. Ryan, Martin Gleave, Yuzhuo Wang, Jiaoti Huang, Ilsa Coleman, Colm Morrissey, Peter S. Nelson, Christopher P. Evans, Primo Lara, Robert E. Reiter, Owen Witte, Matthew Rettig, Christopher K. Wong, Alana S. Weinstein, Vlado Uzunangelov, Josh M. Stuart, George V. Thomas, Felix Y. Feng, Eric J. Small, Joel A. Yates, Zheng Xia, Joshi J. Alumkal
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
Lineage plasticity is increasingly recognized as an emergent resistance mechanism after treatment with androgen receptor signalling inhibitors. To understand determinants of resistance, the authors analyzed the transcriptomes of patient tumor biopsie
Externí odkaz:
https://doaj.org/article/84a852fcb0624999ab330bdca23f4d3f
Autor:
Tamara S. Rodems, Erika Heninger, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Kristin N. Carlson, Madison R. Kircher, Anupama Singh, Timothy E. G. Krueger, David J. Beebe, David F. Jarrard, Douglas G. McNeel, Michael C. Haffner, Joshua M. Lang
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-16 (2022)
Loss of HLA-I gene expression in prostate cancer is associated with repressive chromatin states, which can be reversed by pharmacological DNMT and HDAC inhibition leading to increased activation of co-cultured tumor-specific CD8+ T-cells.
Externí odkaz:
https://doaj.org/article/1153e9cc0b6a481e85909d4a3f28af7d
Autor:
Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin-Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner
Publikováno v:
JCI Insight, Vol 8, Iss 7 (2023)
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the mecha
Externí odkaz:
https://doaj.org/article/bf1e39c95aad42bb924c7ccfb3af7d25